Proliferator-activated receptor-γ has a key role in glucose and lipid metabolism and activation lead to benefits in patients with diabetes. Telmisartan can robustly activate this nuclear receptor as well as blocking the angiotensin II type 1 receptor. This Article assesses whether this dual effect affords telmisartan additional benefits over other angiotensin-II-receptor blockers.